Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinsons with pre-existing diabetes
This specific code applies to therapeutic, prophylactic, or diagnostic injections delivered by a healthcare professional
Back Thorens, B, Hodson, DJ (2024) Building the glucagon-like peptide-1 receptor brick by brick: Revisiting a 1993 Diabetes Classic by Thorens et al, Diabetes, 73, 1027-31
One 2023 review, published in the journal Cells , draws a link between microbes in the intestine and a healthy immune system
The recommended injection sites for GLP-1 medications include the abdomen (at least 2 inches from the navel), the front of the thigh, and the back of the upper arm
Individual experiences vary, and the available safety information continues to evolve as larger Phase 3 studies are completed